Innovations in Klebsiella pneumoniae Vaccine Development: Current Progress and Future Prospects

Klebsiella pneumoniae is a Gram-negative bacterium belonging to the family Enterobacteriaceae.It causes healthcare and community-acquired infections complicated by multidrug resistance (MDR) and hypervirulence.This review provides a comprehensive overview of the current progress and prospects of vaccine development for K. pneumoniae.Several vaccines were explored including next-generation mRNA vaccines and ghost cell vaccines.Each vaccine category and suitable adjuvants was discussed in terms of immunogenicity, safety, production scalability, and stage of development.Despite progress, major challenges incurred are achieving broad strain coverage, avoiding reactogenicity, ensuring mucosal immunity, and simplifying manufacturing.Adjuvant selection, such as alum, CpG, MPLA, and chitosan, plays a critical role in optimizing immune responses.Conjugate and subunit vaccines show strong near-term potential, while mRNA and ghost cell platforms offer exciting long-term prospects.Accelerating these innovations through robust biotechnological infrastructure and scalable production supports SDG 9 by strengthening scientific research, fostering industrial innovation, and building resilient health-related manufacturing capabilities.Advancing these technologies could yield safe, effective, and scalable vaccines to protect high-risk populations against this formidable pathogen.